Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1970 2
1971 5
1972 2
1973 4
1974 3
1975 8
1976 3
1977 5
1978 11
1979 8
1980 7
1981 7
1982 6
1983 6
1984 12
1985 7
1986 5
1987 8
1988 22
1989 29
1990 44
1991 35
1992 34
1993 50
1994 50
1995 39
1996 33
1997 50
1998 55
1999 42
2000 60
2001 57
2002 67
2003 78
2004 56
2005 54
2006 48
2007 74
2008 66
2009 60
2010 73
2011 60
2012 49
2013 75
2014 54
2015 68
2016 64
2017 78
2018 76
2019 53
2020 61
2021 68
2022 63
2023 47
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

1,975 results

Results by year

Filters applied: . Clear all
Page 1
Advances and controversies in management of breast ductal carcinoma in situ (DCIS).
Farante G, Toesca A, Magnoni F, Lissidini G, Vila J, Mastropasqua M, Viale G, Penco S, Cassano E, Lazzeroni M, Bonanni B, Leonardi MC, Ripoll-Orts F, Curigliano G, Orecchia R, Galimberti V, Veronesi P. Farante G, et al. Eur J Surg Oncol. 2022 Apr;48(4):736-741. doi: 10.1016/j.ejso.2021.10.030. Epub 2021 Nov 9. Eur J Surg Oncol. 2022. PMID: 34772587 Review.
Ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive breast cancer. It accounts for 25% of all breast cancers diagnosed, as a result of the expansion of breast cancer screening and is associated with a high survival rate. ...
Ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive breast cancer. It accounts for 25% of all br
Papillary lesions of the breast.
Kulka J, Madaras L, Floris G, Lax SF. Kulka J, et al. Virchows Arch. 2022 Jan;480(1):65-84. doi: 10.1007/s00428-021-03182-7. Epub 2021 Nov 3. Virchows Arch. 2022. PMID: 34734332 Free PMC article. Review.
Papillary lesions of the breast represent a heterogeneous group of lesions including benign papillomas, papillomas with focal epithelial atypia, fully fledged ductal carcinoma in situ (DCIS) or lobular neoplasia, papillary DCIS, encapsulated papillary carcino …
Papillary lesions of the breast represent a heterogeneous group of lesions including benign papillomas, papillomas with focal epithel …
Ductal carcinoma in situ of breast: update 2019.
Badve SS, Gökmen-Polar Y. Badve SS, et al. Pathology. 2019 Oct;51(6):563-569. doi: 10.1016/j.pathol.2019.07.005. Epub 2019 Aug 28. Pathology. 2019. PMID: 31472981 Free PMC article. Review.
Ductal carcinoma in situ is a non-invasive form of breast cancer. Its incidence is increasing due to widespread use of mammographic screening. ...
Ductal carcinoma in situ is a non-invasive form of breast cancer. Its incidence is increasing due to widespread use of …
Management of Ductal Carcinoma In Situ (DCIS) of the Breast: Present Approaches and Future Directions.
Solin LJ. Solin LJ. Curr Oncol Rep. 2019 Mar 5;21(4):33. doi: 10.1007/s11912-019-0777-3. Curr Oncol Rep. 2019. PMID: 30834994 Review.
PURPOSE OF REVIEW: Ductal carcinoma in situ (DCIS; intraductal carcinoma) of the breast is commonly found in an asymptomatic woman on routine screening mammography. ...RECENT FINDINGS: Randomized trials have demonstrated that adding radiation treatment …
PURPOSE OF REVIEW: Ductal carcinoma in situ (DCIS; intraductal carcinoma) of the breast is commonly found in an …
Lobular Carcinoma In Situ.
Wen HY, Brogi E. Wen HY, et al. Surg Pathol Clin. 2018 Mar;11(1):123-145. doi: 10.1016/j.path.2017.09.009. Epub 2017 Dec 8. Surg Pathol Clin. 2018. PMID: 29413653 Free PMC article. Review.
Lobular carcinoma in situ (LCIS) is a risk factor and a nonobligate precursor of breast carcinoma. The relative risk of invasive carcinoma after classic LCIS diagnosis is approximately 9 to 10 times that of the general population. ...
Lobular carcinoma in situ (LCIS) is a risk factor and a nonobligate precursor of breast carcinoma. The relative …
Management of High-Risk Breast Lesions.
Bahl M. Bahl M. Radiol Clin North Am. 2021 Jan;59(1):29-40. doi: 10.1016/j.rcl.2020.08.005. Radiol Clin North Am. 2021. PMID: 33222998 Review.
High-risk breast lesions (HRLs) are a group of heterogeneous lesions that can be associated with a synchronous or adjacent breast cancer and that confer an elevated lifetime risk of breast cancer. ...This article reviews histologic features and clinical prese …
High-risk breast lesions (HRLs) are a group of heterogeneous lesions that can be associated with a synchronous or adjacent breast
Margins in breast cancer: How much is enough?
Pilewskie M, Morrow M. Pilewskie M, et al. Cancer. 2018 Apr 1;124(7):1335-1341. doi: 10.1002/cncr.31221. Epub 2018 Jan 16. Cancer. 2018. PMID: 29338088 Free PMC article. Review.
The appropriate negative margin width for women undergoing breast-conserving surgery for both ductal carcinoma in situ (DCIS) and invasive carcinoma is controversial. ...Consensus guidelines support a negative margin, defined as no ink on tumor, for in …
The appropriate negative margin width for women undergoing breast-conserving surgery for both ductal carcinoma in situ
Papillary neoplasms of the breast-reviewing the spectrum.
Tay TKY, Tan PH. Tay TKY, et al. Mod Pathol. 2021 Jun;34(6):1044-1061. doi: 10.1038/s41379-020-00732-3. Epub 2021 Jan 18. Mod Pathol. 2021. PMID: 33462367 Free article. Review.
Papillary neoplasms of the breast encompass a wide range of tumor types ranging from the benign intraductal papilloma to in situ and invasive papillary carcinomas. In this review, we considered each tumor entity listed under the Papillary Neoplasms category in the l …
Papillary neoplasms of the breast encompass a wide range of tumor types ranging from the benign intraductal papilloma to in situ
Ductal carcinoma in situ: to treat or not to treat, that is the question.
van Seijen M, Lips EH, Thompson AM, Nik-Zainal S, Futreal A, Hwang ES, Verschuur E, Lane J, Jonkers J, Rea DW, Wesseling J; PRECISION team. van Seijen M, et al. Br J Cancer. 2019 Aug;121(4):285-292. doi: 10.1038/s41416-019-0478-6. Epub 2019 Jul 9. Br J Cancer. 2019. PMID: 31285590 Free PMC article. Review.
Ductal carcinoma in situ (DCIS) now represents 20-25% of all 'breast cancers' consequent upon detection by population-based breast cancer screening programmes. ...Further research is needed to gain new insights for improved diagnosis and management of …
Ductal carcinoma in situ (DCIS) now represents 20-25% of all 'breast cancers' consequent upon detection by population-b …
Updates in the Treatment of Breast Cancer with Radiotherapy.
Castaneda SA, Strasser J. Castaneda SA, et al. Surg Oncol Clin N Am. 2017 Jul;26(3):371-382. doi: 10.1016/j.soc.2017.01.013. Epub 2017 May 11. Surg Oncol Clin N Am. 2017. PMID: 28576177 Review.
Breast-conserving therapy is one of the most remarkable achievements of modern cancer care. The authors review the evidence supporting the role of adjuvant radiotherapy as the standard of care for breast cancer after breast-conserving surgery, consensus guide
Breast-conserving therapy is one of the most remarkable achievements of modern cancer care. The authors review the evidence supportin
1,975 results